Acquisition by Rick Winningham of 3075 shares of Jazz Pharmaceuticals subject to Rule 16b-3
JAZZ Stock | USD 121.41 1.18 0.98% |
Slightly above 50% of Jazz Pharmaceuticals' investors are presently thinking to get in. The analysis of overall sentiment of trading Jazz Pharmaceuticals PLC stock suggests that some investors are interested at this time. Jazz Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Jazz Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Jazz |
Filed transaction by Jazz Pharmaceuticals Plc director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Jazz Pharmaceuticals Fundamental Analysis
We analyze Jazz Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jazz Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jazz Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Jazz Pharmaceuticals is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Jazz Pharmaceuticals PLC Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Jazz Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Jazz Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Jazz Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Jazz Pharmaceuticals Related Equities
EXEL | Exelixis | 4.41 | ||||
LEGN | Legend Biotech | 2.59 | ||||
ARGX | Argenx NV | 1.08 | ||||
PCVX | Vaxcyte | 0.02 | ||||
UTHR | United Therapeutics | 0.45 | ||||
ALNY | Alnylam Pharmaceuticals | 1.07 | ||||
BMRN | Biomarin Pharmaceutical | 1.46 | ||||
HALO | Halozyme Therapeutics | 1.79 | ||||
LQDA | Liquidia Technologies | 2.17 | ||||
TECH | Bio Techne | 2.50 | ||||
PTGX | Protagonist Therapeutics | 2.68 | ||||
LRMR | Larimar Therapeutics | 3.43 | ||||
BPMC | Blueprint Medicines | 3.53 | ||||
INCY | Incyte | 3.54 | ||||
RARE | Ultragenyx | 3.62 | ||||
ASND | Ascendis Pharma | 3.90 | ||||
VRDN | Viridian Therapeutics | 4.96 | ||||
INBX | Inhibrx | 5.14 | ||||
DNLI | Denali Therapeutics | 10.12 | ||||
APLS | Apellis Pharmaceuticals | 16.85 |
Additional Tools for Jazz Stock Analysis
When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.